The impact of beta-blockers on mortality and hospitalizations was assessed in the largest randomized trial of patients with both atrial fibrillation (AF) and heart failure with a reduced ejection fraction (HFrEF): the Atrial Fibrillation-Congestive Heart Failure trial.
versus rate (n ¼ 682) control treatment. The study protocol was previously described (6) . In short, patients were required to have a left ventricular ejection fraction (LVEF) #35% with symptomatic congestive heart failure or a LVEF <25%, regardless of symptom status. The trial included patients with at least 1 electrocardiographically documented episode of AF that lasted >6 h or required cardioversion in the preceding 6 months, or an episode of AF that lasted >10 min in the preceding 6 months combined with cardioversion for AF at any time. Patients with AF that persisted for >12 months qualified for the study if sinus rhythm could be maintained for >24 h following cardioversion. The study protocol was approved by each center's institutional review board, and all patients provided written informed consent to participate.
Information regarding the baseline rhythm, pattern of AF (i.e., paroxysmal vs. persistent), and time since first diagnosis of AF were collected. The methodology to compute the proportion of time spent in AF was previously detailed (7) . In brief, AF burden was quantified by dividing time intervals between visits into quartiles. "Sinus rhythm" or "AF" was assigned to each time point for every patient on the basis of electrocardiographic documentation and presence or absence of AF recurrences between visits.
For each patient, the proportion of time spent in AF was calculated by dividing the total time in AF by follow-up duration. For the purposes of this analysis, patients were classified into 2 groups based on whether the proportion of time they spent in AF was equal or superior (i.e., "high AF burden") or inferior (i.e., "low AF burden") to the overall median value for proportion of time spent in AF.
BETA-BLOCKERS. Beta-blockers (i.e., metoprolol, carvedilol, or bisoprolol) were recommended for the treatment of heart failure along with angiotensinconverting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs), aldosterone antagonists in patients with New York Heart Association (NYHA) functional class III or IV symptoms, and implantable cardioverter-defibrillators in selected patients. Recommended targeted doses for beta-blockers were 100 to 200 mg/day for metoprolol, 25 to 50 mg/day for carvedilol, and 10 mg/day for bisoprolol. Beta-blocker status was recorded at baseline and at each follow-up visit.
FOLLOW-UP AND OUTCOMES. Follow-up visits occurred every 4 months for the first 4 years and every 6 months thereafter. The primary outcome was all-cause mortality. Secondary outcomes consisted of cardiovascular mortality, all-cause hospitalizations, cardiovascular hospitalizations, and hospitalizations for worsening heart failure. All outcomes were reviewed and classified by an independent blinded adjudicating committee in the main AF-CHF trial.
STATISTICAL ANALYSIS. A matching propensity score approach was used to overcome indication bias in comparing patients who received and who did not receive beta-blockers. Propensity scores in the full cohort were estimated from a nonparsimonious multivariable logistic regression model in which betablocker use at baseline was modeled as the dependent variable, and the 28 baseline variables listed in Table 1 were included as covariates (8) . These covariates were selected based on consideration of substantive knowledge and statistical associations. By using a greedy matching algorithm, each patient in the control group (n ¼ 229) was matched to a maximum of 2 exposed patients (n ¼ 426) (Figure 1 Cadrin-Tourigny et al.
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Cadrin-Tourigny et al. were considered statistically significant. All analyses Love plot of the absolute standardized differences for the 28 baseline characteristics between patients receiving and not receiving beta-blockers at baseline before and after propensity score matching. ACE ¼ angiotensin converting enzyme; ARB ¼ angiotensin receptor blockers; NYHA ¼ New York Heart Association; TIA ¼ transient ischemic attack.
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RESULTS
BASELINE CHARACTERISTICS. At baseline, 1,085 (79%) patients in the AF-CHF trial received betablockers. In the 291 (21%) patients who did not receive beta-blockers, the reported justification was physician preference in 42%, pulmonary disease in 24%, intolerance in 18%, and other in 16%. Baseline characteristics before and after propensity matching are summarized in Table 1 . Before matching, patients not on beta-blockers were significantly older, had a wider QRS interval, and were less likely to have nonischemic cardiomyopathy. They were less likely to receive an oral vitamin K antagonist and more likely to be on a calcium channel blocker. After propensity matching, there were no significant differences in baseline characteristics between those who received and those who did not receive beta-blockers.
As shown in Figure 2 , post-matching standardized differences for all 28 baseline covariates were <10%.
Matched patients were a mean age of 70 AE 11 years, 81% were men, 14% were non-Caucasian, and 31% had NYHA functional class III or IV symptoms. The mean LVEF was 27 AE 6%, and 50% had ischemic cardiomyopathy. Overall, 96% received an ACE inhibitor or ARB, and 85% received an aldosterone antagonist.
The median AF burden was 34%, 58% were in AF on the baseline electrocardiogram, 58% were diagnosed with AF within 6 months of randomization, and 66% had persistent AF.
MORTALITY. A total of 231 (35%) matched patients died during follow-up: 95 (42%) without betablockers and 136 (31%) with beta-blockers. Corresponding survival curves are depicted in Figure 3 . As summarized in Table 2 , beta-blockers were associated lower rates of hospitalizations for worsening heart failure, acute coronary syndromes, and bradycardia.
BETA-BLOCKERS AND AF CHARACTERISTICS. As noted in Online Table 2 , there was no significant interaction among beta-blockers and pattern of AF The low reported prevalence of AF (17%) in a population with HFrEF was consistent with such a misclassification error (10) . To reconcile the discrepant findings, it could be hypothesized that the mortality benefit associated with beta-blockers in HFrEF was modulated by the proportion of time spent in AF, with Values are n (%).
CI ¼ confidence interval; HF ¼ heart failure; HR ¼ hazard ratio (estimated). Our results were consistent with data from 2 registries (13, 14) . In the Swedish Heart Failure Registry that included 7,392 patients with HFrEF and AF (identified by a single electrocardiogram), betablockers were associated with a 29% reduction in mortality (13) . A second registry of patients with AF included 39,741 subjects with prevalent heart failure (14) . At 1-year follow-up, beta-blockers were associated with 25% lower mortality. However, the study could not distinguish between patients with heart failure and a preserved versus reduced LVEF, nor could it adjust for other important covariates such as NYHA functional class.
Reasons as to why beta-blockers were not associated with a significant reduction in hospitalizations in our study, despite events in >60% of patients, remain 
